| 5TBO: reference: A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malaria., Phillips MA, White KL, Kokkonda S, Deng X, White J, El Mazouni F, Marsh KC, Tomchick DR, Manjalanagara K, Rudra KR, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Shackleford DM, Chiu FC, Campbell M, Jimenez Diaz MB, Ferrer-Bazaga S, Angulo-Barturen I, Martinez-Martinez MS, Lafuente-Monasterio MJ, Kaminsky W, Silue K, Zeeman AM, Kocken C, Leroy D, Blasco B, Rossignol E, Rueckle T, Matthews D, Burrows JN, Waterson D, Palmer MJ, Rathod PK, Charman SA, ACS Infect Dis. 2016 Sep 17. PMID: 27641613 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).